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A B S T R A C T
Obesity has a deteriorating impact on women with PCOS, although prevalence and the impact of specific traits of
PCOS remain inconstant in different populations. Therefore, the aim of this study was to explore the differences in clini-
cal, hormonal and metabolic features between obese and nonobese Croatian women diagnosed as having PCOS accord-
ing to Rotterdam consensus criteria. The study included 74 obese and 208 nonobese women with PCOS. Clinical, bio-
chemical and metabolic variables were compared among those PCOS subgroups. Obese subjects with PCOS had a higher
risk of developing oligo-amenorrhea (OR 3.7; 95% CI, 1.1–12.5) and lower risk for developing hirsutism and acne (OR
0.2; 95% CI, 0.1–0.3 and OR 0.8; 95% CI 0.5–1.4, respectively). Obese PCOS subjects also had a higher risk of developing
hyperandrogenemia (OR 2.5; CI 95% 0.9–6.7), insulin resistance (OR 4.5; CI 95%, 2.6–7.9), hypercholesterolemia (OR
5.0, CI 95% 2.5–10.2), hypertriglyceridemia (OR 5.2; 95% CI, 2.9–9.2) as well as elevated serum CRP levels (OR 4.1; 95%
CI 1.4–12.2) compared to nonobese PCOS women. In conclusion, nonobese Croatian women with PCOS are more in-
clined to cosmetic problems associated with PCOS then metabolic ones. This is the first study to report the impact of obe-
sity on acne and irregular menses as a study outcome. Obesity deteriorates menstrual regularity, insulin sensitivity and
lipid profile in Croatian women with PCOS; therefore one of the fundamental treatment strategies of PCOS should be
obesity prevention.
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Introduction
The polycystic ovary syndrome (PCOS) was first rec-
ognized by Stein and Leventhal in 1935 as a triad of
amenorrhea, obesity and hirsutism1. Since then, the
PCOS has gained clinical and public health importance
as it is very common, affecting up to one in five women of
reproductive age2. The importance of the PCOS is not
only in its numerosity, but also in its substantial and di-
verse clinical consequences including reproductive (in-
fertility, hyperandrogenism, hirsutism), metabolic (insu-
lin resistance, impaired glucose tolerance, type 2 dia-
betes mellitus, adverse cardiovascular risk profiles) and
psychological features (increased anxiety, depression and
worsened quality of life)3, which make this syndrome a
major health risk in reproductive age women4. It is esti-
mated that the economic burden of the PCOS in the USA
is about 4 billion dollars per year, making the PCOS not
only a health, but also a significant economic burden5.
Obesity and insulin resistance often accompany
PCOS, although those parameters are not considered
necessary to perform diagnosis. Unitly recently health
care providers concentrated on skin and reproductive
complications of the PCOS, not beening much aware of
obesity and its profound effect on clinical, hormonal and
metabolic features of PCOS. There are great ethnic dif-
ferences in the frequency of obesity among women with
the PCOS that can be explained with diverse gene-gene
and gene-environmental interaction in distinct popula-
tion6. However, the exact prevalence of obesity in PCOS
patients is not known due to the lack of representative
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population data. The US study reported that the preva-
lence of obesity in women with PCOS has increased from
51% in 1987–1990 to 74% in 2000–20027. Controversy, a
study in Italy reported that only 14% of women with
PCOS were obese8. We recently published that 23.8% of
Croatian PCOS have excess weight9. The effect of being
obese on clinical, hormonal, and metabolic aspects of
PCOS is inconsistent from the existing literature, and
differ among various ethnical groups.
Therefore, the aim of the study was to explore the dif-
ference in clinical, hormonal and metabolic features be-




In total, 282 women fulfilling the criteria for PCOS
(average age, 27.0±5.8 years; range, 18–38 years) were
enrolled in the study. The adolescent girls were not in-
cluded because there is no agreement concerning how to
diagnose PCOS in adolescence considering that many
features characteristic to PCOS may be the result of nor-
mal evolution from girls to adulthood10. Women older
than age 38 were also excluded considering the well-
-known decline of androgens with age11. All studied sub-
jects were enrolled during their treatment at the Division
of Human Reproduction and Gynecologic Endocrinology
of the Department of Obstetrics and Gynecology, Clinic
for Women’s diseases, Zagreb University Hospital Cen-
tre, Croatia between October 2007 and January 2012.
None of the patients had diabetes, hypertension and car-
diovascular disease. Any medications known to affect sex
hormones or carbohydrate metabolism were discontin-
ued at least six months prior to enrolment.
The diagnosis of PCOS was based on the Rotterdam
consensus criteria2. Menstrual cycles were defined as: a)
regular (menstrual interval of 21 to 35 days with normal
progesterone levels >22.5 nmol/L on 21.–24. day of the
cycle, determined in two consecutive menstrual cycles);
b) irregular – oligomenorrhea or amenorrhea (intermen-
strual interval of 36 day – 6 months or 6 months or lon-
ger, respectively). Hirsutism was assessed by a single in-
vestigator and defined by a Ferriman-Gallwey index
score >8 (FG>8)12. Hyperandrogenemia was defined as a
serum level of total testosterone (TT) higher than 2.0
nmol/L or free testosterone (FT) greater than 26 pmol/L
or androstendione (A) greater than 12 nmol/L or dehy-
droepiandrosterone sulphate (DHEAS) greater than 10
µmol/L. Polycystic ovaries (PCO) were defined by the
presence of 12 or more follicles measuring 2 to 9 mm in
diameter and/or increased ovarian volume (>10 mL) by
transvaginal ultrasound (TVUS)13. To avoid the inter-ob-
servational variations the same examiner performed all
the ultrasonographic exams. Body mass index was calcu-
lated as weight in kilograms divided by square of height
in meters. Obesity was defined as BMI >25 kg/m2. Other
endocrinopaties and related disorders were excluded by
measuring basal serum 17-hydroxyprogesterone (17-
-OHP), prolactin (PRL), follicle stimulating hormone
(FSH), luteinizing hormone (LH), and thyroid stimu-
lated hormone (TSH) levels. All the patients were re-
cruited in the early follicular phase of the spontaneous or
progesterone induced menstrual cycle (day 3–5) when
blood samples for biochemical and hormonal analysis
was drawn and TVUS was performed.
The University of Zagreb Medical School Ethics Com-
mittee approved the study protocol No. 04–1116–2006.
Informed written consent was obtained from all women
enrolled in the study.
Biochemical analysis
Serum LH, FSH, TSH, PRL, and TT concentrations
were determined by chemiluminescent immunometric
assays using LH-Vitros, FSH-Vitros, TSH-Vitros, Pro-
lactine-Vitros and Testosterone-Vitros, respectively (Or-
tho Clinical Diagnostics, Johnson&Johnson, Rochester,
NY, USA). Serum SHBG, DHEAS and A levels were mea-
sured using chemiluminescent immunometric assays
(SHBG-Immulite, DHEAS-Immulite and Androstendio-
ne-Immulite, respectively) (Siemens Healthcare Diag-
nostics Inc., Deerfield, IL, USA). The concentration of
17-OHP was determined by a solid phase enzyme-linked
immunosorbent assay (ELISA) based on the principle of
the competitive binding (DRG-diagnostics, Marburg,
Germany). The intra–assay and inter-assay coefficients
of variation ranged between 1.5 and 7.9 %. The plasma
glucose level (Glc) was determined by the UV-photomet-
ric hexokinase method and the serum insulin (Ins) level
by chemiluminescent immunometric assay using Insulin
– Immulite, respectively (Siemens Healthcare Diagnos-
tics Inc., Deerfield, IL, USA). Total cholesterol and tri-
glycerides were measured by standard routine enzymatic
photometric assay. HDL cholesterol was determined after
precipitation of VLDL and LDL with dextran sulphate
and MgCl2. C-reactive protein (CRP) was determined by
a particle enhanced turbidimetric immunoassay (PETIA)
technique with sensitivity of the test 0.1 mg/L. Free tes-
tosterone (FT) was calculated from TT and SHBG as pre-
viously described14 using a web-based calculator (http://
www.issam.ch/freetesto.htm). Insulin resistance (IR) was
quantified using the homeostatic model assessment of IR
(HOMA–IR) (fasting insulin (mU/L) x fasting glucose
(mmol/L)) / 22.5)15. Insulin resistance was defined by
HOMA-IR of 2.5 or higher based on original HOMA
research15. The LDL cholesterol concentration was cal-
culated mathematically from the total cholesterol, tri-
glyceride and HDL cholesterol concentrations using the
Friedewald’s formula16: LDL cholesterol (mmol/L) = to-
tal cholesterol (mmol/L) – HDL cholesterol (mmol/L) –
triglycerides (mmol/L) / 2.2. All the laboratory analysis
was performed at the Department of Clinical Biochemis-
try of Clinical Hospital Center Zagreb, Croatia.
Statistical analysis
Data are presented as X±SD or percentage unless
otherwise indicated. We used the independent Student’s
T-test to compare the values of the means between obese










and nonobese PCOS patients. Differences in categorical
characteristics between obese and nonobese PCOS pa-
tients were assessed using c2-test. Logistic regression
analyses were used to estimate the odds ratios (ORs) and
95% confidence intervals (95%CIs). All statistical analy-
ses were done using the SPSS for Windows (version 15.0;
SPSS Inc., Chicago, IL, USA). A p value <0.05 was con-
sidered statistically significant.
Results
The comparison of clinical, hormonal and metabolic
features between obese and nonobese PCOS subjects are
summarized in Tables 1 and 2.
Obese subjects with PCOS had a higher risk of devel-
oping oligo-amenorrhea (95.9% vs. 86.5%; OR 3.7; 95%
CI, 1.1–12.5, p<0.026) while the risk for developing
hirsutism was lower than in nonobese subjects (44.6% vs.
80.8%; OR 0.2; 95% CI, 0.1–0.3. p<0.01). Obese subjects
also presented with lower incidence of acne than non-
obese PCOS patients (48.6% vs. 53.8%; OR 0.8; 95% CI
0.5–1.4, p<0.442) although the difference was not signif-
icant. There was no difference in the prevalence of PCO
appearance on ultrasound between both examined groups
(Table 1). OR for the incidence of some clinical and bio-
chemical manifestations in obese versus nonobese wo-
men with PCOS are presented on Figure 1.
Obese women with PCOS had significantly higher se-
rum levels of free T (50.2±19.1 vs. 39.8±14.4, p<0.001)
and significantly lower levels of SHBG (32.7±15.1 vs.
43.4±19.7, p<0.001) than nonobese women with PCOS
(Table 2). Moreover, obese PCOS subjects had a higher
risk of developing hyperandrogenemia (93.2% vs. 84.6%;
OR 2.5; CI 95% 0.9–6.7) as it is presented on Figure 1.
The overall prevalence of insulin resistance was ob-
served in 31.6%. of PCOS patients. Elevated serum levels
of total cholesterol was found in 14.2% of PCOS patients
while 37.6% of patients had elevated serum levels of tri-
glycerides. Decreased serum levels of HDL were found in
only 2.5 % and elevated serum levels of LDL and CRP in
12.4% and 5%, respectively.
Obese PCOS patients had significantly higher serum
levels of HOMA-IR compared to nonobese PCOS (3.4±
2.1 vs. 2.0±1.2, p<0.001) as well as elevated serum levels
of total cholesterol (4.8±0.3 vs. 4.5±0.4, p<0.001), tri-
glycerides (1.8±0.3 vs. 1.3±0.4, p<0.001), LDL choles-
terol (2.6±0.4 vs. 2.4±0.5, p<0.001) and CRP (2.3±0.6
vs. 2.1±0.6, p<0.002) (Table 2.). Moreover, obese women
with PCOS had a higher risk of developing insulin resis-
tance (56.8% vs. 22.6%; OR 4.5; CI 95%, 2.6–7.9), hyper-
cholesterolemia (31.1% vs. 8.2%; OR 5.0, CI 95% 2.5–
10.2), hypertriglyceridemia (66.2% vs. 27.4%; OR 5.2;
95% CI, 2.9–9.2) as well as elevated serum CRP levels
(10.8% vs. 2.9%; OR 4.1; 95% CI 1.4–12.2) (Figure 1).
Discussion and Conclusion
In Stein and Leventhal’s original description1, obe-
sity, together with hirsutism and infertility, represents
one of the characteristics of the PCOS. Since then, al-
though obesity has an important pathophysiological im-
pact on PCOS, and obese PCOS women are described by
aggravated endocrine and metabolic profiles and poorer
fertility, the specific obesity-PCOS phenotype has not
been acknowledged. As the obesity is most commonly
caused by a combination of excessive food energy intake,
lack of physical activity, and genetic susceptibility it is
not suprising that its prevalence of obesity in PCOS pa-
tients vary in distinct population. Futhermore, published
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TABLE 1
CLINICAL CHARACTERISTICS OF PCOS PATIENTS
Total Nonobese Obese p value1
No. of cases 282 208 74
Age (years) 27.0±5.8 27.0±5.8 27.1±5.9 0.900
BMI (kg/m2) 24.6±4.9 22.4±1.8 31.0±5.4 <0.001
Oligo-amenorrhea (%) 89.0 86.5 95.9 0.026
Hirsutism (%) 71.3 80.8 44.6 <0.001
Acne (%) 52.5 53.8 48.6 0.442
US findings of PCO (%) 96.5 97.1 94.6 0.314
BMI: body mass index, US: ultrasound, PCO: polycystic ovaries.
1 Students’ t-test was used for continuous and c2-test for categorical variables
Fig. 1. Odds ratio for the incidence of some clinical manifesta-










studies have not been in consensus on whether excess
BMI would have a significant impact on reproductive and
metabolic features of PCOS.
In the present study we evaluated the difference in
the clinical, hormonal and metabolic features between
obese and nonobese women with PCOS. To our knowl-
edge this is the first study to examine the impact of obe-
sity on clinical and metabolic traits in the Croatian popu-
lation with PCOS.
It has been proposed that obesity is associated with a
greater prevalence of menstrual irregularities10, although
no studies reported irregular menses as outcomes. We
found that obese women have a higher risk of developing
oligo-amenorrhea (OR 3.7; 95% CI, 1.1–12.5). This is pos-
sibly the consequence of additional disturbance of endo-
crine and metabolic profile associated with obesity in
PCOS patients17, which was also observed in our study.
Only a few studies investigated the effect of body
weight on the prevalence of hirsutism using Ferriman-
-Gallwey scores but found no significant association6,18–20
Obese PCOS patients present with lower serum SHBG
levels and therefore higher free T levels in contrast to
nonobese PCOS patients17. This was also observed in our
study. Consequently, it would be expected to find more
severe clinical signs of hyperandrogenism in obese wo-
men with PCOS. In contrast, we found that hirsutism oc-
curred less frequently in obese than in nonobese PCOS
group (44.6% vs. 80.8%, p<0.001). This finding could be
explained by the fact that adipose tissue increases the
aromatase activity, the enzyme that converts testoster-
one to estradiol. Aromatase is also present in the seba-
ceous glands so it may play a »detoxifying« role by re-
moving excess androgens21. No previous studies reported
acne as study outcome. We found that obese PCOS pa-
tients tend to have lower frequency of acne than non-
obese but this finding was not significantly different be-
tween the groups studied (48.6% vs. 53.8%, p=0.442).
This is consistent with the agreement that acne is not
commonly associated with hyperandrogenism17. More-
over, the presence of acne is known to be associated with
the number of androgens receptors within the pilose-
baceous unit as well as on 5a-reductase activity, the en-
zyme that converts testosterone to dihydrotestosterone
(DHT)22.
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TABLE 2
HORMONAL AND METABOLIC CHARACTERISTICS OF PCOS PATIENTS
Total Nonobese Obese p value1
No. of cases (%) 282 208 74
FSH (IU/L) 3.6±1.2 3.7±1.2 3.4±1.1 0.067
LH (IU/L) 8.9±4.4 9.9±4.7 6.3±2.2 <0.001
TT (nmol/L) 2.4±0.5 2.3±0.4 2.5±0.8 0.067
FT (pmol/L) 42.5±16.4 39.8±14.4 50.2±19.1 <0.001
FT >26.0 (pmol/L) (%) 86.9 84.6 93.2 0.059
A (nmol/L) 11.4±4.9 11.6±5.1 10.8±4.2 0.180
DHEA-S (mmol/L) 6.7±2.8 6.6±2.7 7.1±3.0 0.239
SHBG (nmol/L) 40.6±19.1 43.4±19.7 32.7±15.1 <0.001
Glucose (mmol/L) 4.4±0.5 4.4±0.5 4.5±0.5 0.010
Insulin (mIU/L) 11.8±7.8 10.1±6.0 16.9±9.8 <0.001
HOMA-IR 2.4±1.6 2.0±1.2 3.4±2.1 <0.001
HOMA-IR >2.5 (%) 31.6 22.6 56.8 <0.001
Total cholesterol (mmol/L) 4.6±0.4 4.5±0.4 4.8±0.3 <0.001
Total cholesterol >5 mmol/L (%) 14.2 8.2 31.1 <0.001
HDL cholesterol (mmol/L) 1.5±0.2 1.5±0.2 1.4±0.2 <0.001
HDL cholesterol <1.2 mmol/L (%) 2.5 1.9 4.1 0.312
LDL cholesterol (mmol/L) 2.5±0.4 2.4±0.5 2.6±0.4 <0.001
LDL cholesterol >3 mmol/L (%) 12.4 11.1 16.2 0.248
Triglycerides (mmol/L) 1.4±0.3 1.3±0.4 1.8±0.3 <0.001
Triglycerides >1.7 mmol/L (%) 37.6 27.4 66.2 <0.001
CRP (mg/L) 2.1±0.6 2.1±0.6 2.3±0.6 0.002
CRP >3 mg/L (%) 5 2.9 10.8 0.007
FSH: follicle stimulating hormone, LH: luteinizing hormone, TT: total testosterone, FT: free testosterone, DHEAS: dehydroepian-
drosterone sulphate, SHBG: sex hormone binding globulin, HOMA-IR: homeostatic model assessment of insulin resistance, HDL:
high-density lipoprotein, LDL: low-density lipoprotein, CRP: C-reactive protein









It is well established that obese PCOS women present
with greater insulin resistance23,24 which is in agreement
with our findings. The overall incidence of insulin resis-
tance observed in our study was lower than previously
reported in other populations of PCOS patients23,24. This
could be related to genetic factors that modulate sensitiv-
ity to insulin as well as environmental factors25. Rani-
lovic et al. reported that Croatian adults have a high level
of similarity of eating habits with Italians, practicing
cardio- protective Mediterranean diet, which could con-
tribute to lower insulin resistance observed26.
We found that the obese women with PCOS present
with higher levels of LDL, triglyceride and total choles-
terol as well as lower levels of HDL than nonobese which
is concurrent with the conclusions of the Amsterdam
ESHRE /ASRM 3rd consensus and recently published
meta analysis that obesity is associated with poorer met-
abolic health in PCOS17,27. Additionally it is recognized
that insuline resistance exaggerates dislypidemia28,29. Al-
though the overall incidence of insulin resistance was
low in our group of PCOS patients (31.6%) we found high
incidence of hypertriglyceridemia in both studied groups
(overall 37.6%, obese 66.2% and nonobese 27.4%). Ele-
vated serum levels of triglycerides that we observed are
most likely the result of concurrent hyperandrogenemia
since androgens stimulate the release of free fatty acids
into circulation29. Moreover, increased free fatty acids in
the liver stimulate the secretion of VLDL thus increasing
serum triglyceride levels29. Chapman et al. reported in-
creased early risk for cardiovascular disease in patients
experiencing remote hypertriglyceridemia29.
Further more, PCOS is belived to be a proinflamatory
state aggravated with inflammatory factors produced
from the fat tissue30. The recently published metaana-
lysis by Escobar Moreale et al. indicated that elevated
CRP is a circulating marker of the proinflammatory
state in PCOS independently of obesity although the de-
gree of elevation in CRP levels was much greater when
obesity is present31. Concurrent with their findings obese
PCOS patients in our studied group presented with
higher serum CRP levels compared to nonobese PCOS
(2.3±0.6 vs. 2.1±0.6 p= 0.002). It has been proposed that
CRP levels of <1, 1 to 3, and >3 mg/l correspond to low-,
moderate-, and high-risk groups for future cardiovascu-
lar events32. Although overall incidence of elevated se-
rum CRP levels above 3 mg/l was low in our study, obese
women with PCOS had a higher risk for eleveated serum
CRP compared to nonobese PCOS therefore they may
represent a high risk group for future adverse cardiovas-
cular events.
In conclusion we can state that nonobese Croatian
women with PCOS are more inclined to cosmetic prob-
lems associated with PCOS than metabolic ones. This
study observed that obesity deteriorates menstrual regu-
larity, insulin sensitivity and lipid profile therefore one of
the fundamental treatment strategies of PCOS should be
obesity prevention. Considering there is growing preva-
lence of obesity in Croatia33–37 as well as rising in child-
hood obesity38 we could expect more pronounced meta-
bolic consequences of PCOS in following years.
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KLINI^KE, HORMONSKE I METABOLI^KE KARAKTERISTIKE PCOS PACIJENTICA
U HRVATSKOJ U OVISNOSTI O TJELESNOJ TE@INI
S A @ E T A K
Pretilost ima negativan utjecaj na `ene s PCOS-om. Istra`ivanja o u~estalost i utjecaju pretilosti na specifi~ne simp-
tome PCOS daju nedosljedne rezultate. Do sada nisu objavljene studije kojima je utjecaj debljine kod pacijentica s PCOS
na redovitost menstruacija i akne bio krajni ishod. Cilj ovog rada bio je istra`iti razlike u klini~kim, metaboli~kim i
hormonskim zna~ajkama izme|u pacijentica sa sindromom policisti~nih jajnika (PCOS) pretjerane i normalne tjelesne
mase kod kojih je dijagnoza postavljena prema Rotterdamskim kriterijima. U istra`ivanje je uklju~eno 74 PCOS pa-
cijentice pretjerane i 208 PCOS pacijentice normalne tjelesne mase. Uspore|ivane su njihove klini~ke, metaboli~ke i
hormonske zna~ajke. Zabilje`ili smo da PCOS pacijentice sa pretjeranom tjelesnom masom imaju vi{i rizik za razvoj
oligo-amenoreje (OR 3,7; 95% CI, 1,1–12,5) te ni`i rizik za pojavu hirzutizma i akni (OR 0,2; 95% CI, 0,1–0,3 i OR 0,8;
95% CI 0,5–1,4). U skupini PCOS pacijentica sa pretjeranom tjelesnom masom tako|er je zabilje`en vi{i rizik za nasta-
nak hiperandrogenemije (OR 2,5; CI 95% 0,9–6,7), inzulinske rezistencije (OR 4,5; CI 95%, 2,6–7,9), hiperkolestero-
lemije (OR 5,0, CI 95% 2,5–10,2), hipertriglicidemije (OR 5,2; 95% CI, 2,9–9,2) kao i povi{enih vrijednosti C-reaktivnog
proteina (CRP) u serumu (OR 4,1; 95% CI 1,4–12,2), u usporedbi s PCOS pacijenticama normalne tjelesne mase. U
zaklju~ku, PCOS pacijentice normalne tjelesne mase u Hrvatskoj sklonije su kozmeti~kim zna~ajkama PCOS-a u odno-
su na metaboli~ke. Ovo istra`ivanje potvr|uje da pretjerana tjelesna masa pogor{ava poreme}aje ciklusa, osjetljivost na
inzulin i lipidni profil kod PCOS pacijentica stoga prevencija pretjerane tjelesne mase mora biti jedna od temeljnih
strategija lije~enja PCOS-a.
D. Pavi~i} Baldani et al.: Obesity and PCOS, Coll. Antropol. 37 (2013) 2: 465–470
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